llion). Guidance reflects SS revenue growth of 3%-5% (vol 1-2% / pricing/mix 2-3%), flat margins and -300 bps of EBITDA growth headwinds from lower HITECH and higher stock-based comp. ACA adds -1.5% to growth (at the mid-point) or -5100M. Organic/base growth works out to be -2% to -5% growth adjusting

of uninsured patient mix seems like a reasonable starting point New estimates. We are making modest adjustments to our estimates to reflect lower HITECH and slower ACA ramp. 2014 EBITDA and EPS move to $7.058 / $3.92 from $7.1458 / $4.17, putting us above HCA guidance ranges ($6.608- $6.85B EBITDA /